DS-5141b

Daiichi Sankyo Co., Ltd. · Phase 2 active Small molecule Quality 0/100

At a glance

Generic name	DS-5141b
Also known as	Renadirsen
Sponsor	Daiichi Sankyo Co., Ltd.
Modality	Small molecule
Phase	Phase 2

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Long-term, Extension Study of DS-5141b in Patients With Duchenne Muscular Dystrophy (PHASE2)
Study of DS-5141b in Patients With Duchenne Muscular Dystrophy (PHASE1, PHASE2)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

DS-5141b CI brief — competitive landscape report
DS-5141b updates RSS · CI watch RSS
Daiichi Sankyo Co., Ltd. portfolio CI